The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices
Journal of Medical Internet Research · 2026-09-30 · 28 · e112391-e112391
DOI: 10.2196/112391 ↗At a glance
Journal article in Journal of Medical Internet Research, published online on 2026-09-30. Written by Tejas S Athni. Major MEDLINE topics: United States Food and Drug Administration, Artificial Intelligence, Equipment and Supplies, Device Approval. The full text is freely available in PubMed Central. Funded by: NIGMS NIH HHS.
Abstract (original language)
As the pace of evolution and nature of AI-based technologies outgrow traditional frameworks for evaluation, regulatory bodies are developing new models to keep up. In this News and Perspectives article, JMIR Correspondent Tejas Athni reports on the US Food and Drug Administration’s (FDA’s) new Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot for AI-enabled medical devices.
Subjects
MeSH terms (MEDLINE)
Author keywords
Funding
- NIGMS NIH HHS
Cite
APA
Athni, T. S. (2026). The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices. Journal of Medical Internet Research, 28, e112391-e112391. https://doi.org/10.2196/112391
Vancouver
Athni TS. The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices. Journal of Medical Internet Research. 2026;28:e112391-e112391. doi:10.2196/112391
BibTeX
@article{Athni2026,
author = {Athni, Tejas S},
title = {The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices},
journal = {Journal of Medical Internet Research},
year = {2026},
volume = {28},
pages = {e112391--e112391},
doi = {10.2196/112391}
}
EUVIMED